Oportuzumab monatox - Sesen Bio

Drug Profile

Oportuzumab monatox - Sesen Bio

Alternative Names: Anti-ECAM exotoxin A fusion protein; Proxinium; VB-4847; VB-845; VB4-845; Vicinium

Latest Information Update: 13 Aug 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Zurich
  • Developer National Cancer Institute (USA); Sesen Bio; Viventia Biotechnologies
  • Class Antineoplastics; Drug conjugates; Immunotoxins; Monoclonal antibodies; Recombinant fusion proteins
  • Mechanism of Action Protein synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Head and neck cancer
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Bladder cancer
  • Phase II/III Head and neck cancer
  • No development reported Liver cancer; Ovarian cancer

Most Recent Events

  • 09 Aug 2018 Oportuzumab monatox - Sesen Bio receives Fast Track designation for Bladder cancer [Intravesicular] (Late-stage disease, Second-line therapy or greater) in USA
  • 21 May 2018 Efficacy and adverse events data from the phase III VISTA trial in Bladder cancer presented at the 113th Annual Meeting of the American Urological Association (AUA-2018)
  • 16 May 2018 Eleven Biotherapeutics is now called Sesen Bio
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top